IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Laboratory of Molecular Pharmacology, Via Giuseppe La Masa 19, 20156 Milan, Italy.
Int J Mol Sci. 2018 May 24;19(6):1569. doi: 10.3390/ijms19061569.
Ovarian mucinous tumors represent a group of rare neoplasms with a still undefined cell of origin but with an apparent progression from benign to borderline to carcinoma. Even though these tumors are different from the other histological subtypes of epithelial ovarian neoplasms, they are still treated with a similar chemotherapeutic approach. Here, we review its pathogenesis, molecular alterations, (differential) diagnosis, clinical presentation and current treatment, and how recent molecular and biological information on this tumor might lead to better and more specific clinical management of patients with mucinous ovarian carcinoma.
卵巢黏液性肿瘤是一组罕见的肿瘤，其细胞起源仍不明确，但明显具有从良性到交界性再到癌的进展过程。尽管这些肿瘤与其他组织学类型的上皮性卵巢肿瘤不同，但它们仍采用类似的化疗方法进行治疗。在这里，我们回顾了其发病机制、分子改变、（鉴别）诊断、临床表现和当前治疗方法，以及最近关于该肿瘤的分子和生物学信息如何可能导致更好和更具针对性的黏液性卵巢癌患者的临床管理。
